CLBS
Income statement / Annual
Last year (2024), Caladrius Biosciences, Inc.'s total revenue was $1.00 M,
and the percentage change from the previous year is not available.
In 2024, Caladrius Biosciences, Inc.'s net income was -$19.99 M.
See Caladrius Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2024 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$1.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$35.28 M |
$22.49 M |
$17.94 M |
$14.67 M |
| Cost of Revenue |
$0.00
|
$29.05 M
|
$19.15 M
|
$20.09 M
|
$16.99 M
|
$27.59 B
|
$31.14 M
|
$20.16 M
|
$15.68 M
|
$12.95 M
|
| Gross Profit |
$0.00
|
-$29.05 M
|
-$19.15 M
|
-$20.09 M
|
-$16.99 M
|
-$27.59 B
|
$4.15 M
|
$2.33 M
|
$2.26 M
|
$1.72 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.12
|
0.1
|
0.13
|
0.12
|
| Research and Development Expenses |
$11.33 M
|
$17.68 M
|
$9.25 M
|
$10.80 M
|
$7.59 M
|
$15.84 M
|
$15.11 M
|
$23.90 M
|
$29.19 M
|
$16.92 M
|
| General & Administrative Expenses |
$12.08 M
|
$11.37 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.74 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.08 M
|
$11.37 M
|
$9.89 M
|
$9.30 M
|
$9.39 M
|
$11.75 B
|
$20.37 B
|
$30.01 B
|
$30.81 B
|
$21.61 B
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.38 M
|
$30.01 M
|
$30.81 M
|
$21.61 M
|
| Operating Expenses |
$23.41 M
|
$29.05 M
|
$19.15 M
|
$20.09 M
|
$16.99 M
|
$27.59 M
|
$35.48 M
|
$53.91 M
|
$60.00 M
|
$38.53 B
|
| Cost And Expenses |
$0.00
|
$29.05 M
|
$19.15 M
|
$20.09 M
|
$16.99 M
|
$27.59 M
|
$66.62 M
|
$74.06 M
|
$75.68 M
|
$51.48 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.00 K
|
$377.77 K
|
$1.86 M
|
$2.13 M
|
$755.70 K
|
$281.42 K
|
| Depreciation & Amortization |
$0.00
|
$55.00 K
|
$63.00 K
|
$65.00 K
|
$225.00 K
|
$372.00 K
|
$2.74 M
|
$2.69 M
|
$2.19 M
|
$1.61 M
|
| EBITDA |
$0.00 |
-$28.92 M |
-$18.96 M |
-$19.30 M |
-$15.94 M |
$12.20 M |
-$27.92 M |
-$93.31 M |
-$52.03 M |
-$36.31 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-0.79
|
-4.15
|
-2.9
|
-2.48
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-0.87
|
-4.27
|
-3091.94
|
-2.59
|
| Total Other Income/Expenses Net |
$0.00
|
$29.13 M
|
$19.28 M
|
$20.83 M
|
$0.00
|
$16.14 B
|
-$2.51 M
|
$15.60 B
|
$55.41 B
|
$780.10 M
|
| Income Before Tax |
-$20.78 M
|
-$28.97 M
|
-$19.01 M
|
-$19.35 M
|
-$16.17 M
|
-$27.70 M
|
-$33.17 M
|
-$98.25 M
|
-$55.57 M
|
-$38.71 M
|
| Income Before Tax Ratio |
-20.78
|
0
|
0
|
0
|
0
|
0
|
-0.94
|
-4.37
|
-3.1
|
-2.64
|
| Income Tax Expense |
-$798.00 K
|
-$1.51 M
|
-$10.87 M
|
$9.00 K
|
$5.00 K
|
-$11.53 M
|
$138.04 K
|
-$17.24 M
|
-$104.00 K
|
$780.10 K
|
| Net Income |
-$19.99 M
|
-$27.47 M
|
-$8.14 M
|
-$19.36 M
|
-$16.17 M
|
-$16.17 M
|
-$33.31 M
|
-$81.01 M
|
-$55.47 M
|
-$39.49 M
|
| Net Income Ratio |
-19.99
|
0
|
0
|
0
|
0
|
0
|
-0.94
|
-3.6
|
-3.09
|
-2.69
|
| EPS |
-2.4 |
-1.78 |
-0.53 |
-1.88 |
-1.67 |
-1.8 |
-5.09 |
-16.7 |
-16.93 |
-19.27 |
| EPS Diluted |
-2.4 |
-1.78 |
-0.53 |
-1.88 |
-1.67 |
-1.8 |
-5.09 |
-16.7 |
-16.93 |
-19.27 |
| Weighted Average Shares Out |
$8.33 M
|
$11.87 M
|
$15.44 M
|
$10.33 M
|
$9.69 M
|
$8.97 M
|
$6.55 M
|
$4.85 M
|
$3.28 M
|
$2.05 M
|
| Weighted Average Shares Out Diluted |
$8.33 M
|
$11.87 M
|
$15.44 M
|
$10.33 M
|
$9.69 M
|
$8.97 M
|
$6.55 M
|
$4.85 M
|
$3.28 M
|
$2.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
